McKesson rises after raising annual profit forecast

Shares of U.S. drug distributor McKesson MCK.N up 2% at $837.96 after the bell

MCK raises annual profit forecast, betting on strong growth in its oncology and specialty drug distribution businesses

Expects annual adjusted EPS in the range of $38.80 to $39.20, compared to its previous outlook of $38.35 to $38.85

Posts Q3 revenue of $106.16 billion, compared to expectations of $105.86 billion — data compiled by LSEG

Reports quarterly adjusted EPS of $9.34, beating analysts' estimates of $9.22

Stock rose 43% in 2025